−88.33MXN
−4.06 BMXN
4.60 BMXN
38.78 M
About AXSOME THERAPEUTICS INC
Sector
Industry
CEO
Herriott Tabuteau
Website
Headquarters
New York
Employees (FY)
545
Founded
2012
FIGI
BBG012N09JQ9
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AXSM is 1190.00 MXN — it has decreased by 8.48% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange AXSOME THERAPEUTICS INC stocks are traded under the ticker AXSM.
AXSOME THERAPEUTICS INC is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
AXSM stock is 9.27% volatile and has beta coefficient of 0.98. Check out the list of the most volatile stocks — is AXSOME THERAPEUTICS INC there?
AXSM earnings for the last quarter are −23.01 MXN per share, whereas the estimation was −20.97 MXN resulting in a −9.70% surprise. The estimated earnings for the next quarter are −19.90 MXN per share. See more details about AXSOME THERAPEUTICS INC earnings.
AXSOME THERAPEUTICS INC revenue for the last quarter amounts to 1.01 B MXN despite the estimated figure of 956.40 M MXN. In the next quarter revenue is expected to reach 1.18 B MXN.
Yes, you can track AXSOME THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
AXSM net income for the last quarter is −1.68 B MXN, while the quarter before that showed −1.08 B MXN of net income which accounts for −54.55% change. Track more AXSOME THERAPEUTICS INC financial stats to get the full picture.
Today AXSOME THERAPEUTICS INC has the market capitalization of 58.01 B, it has decreased by 4.63% over the last week.
No, AXSM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AXSM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AXSOME THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 545.00 employees. See our rating of the largest employees — is AXSOME THERAPEUTICS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AXSOME THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AXSOME THERAPEUTICS INC stock shows the buy signal. See more of AXSOME THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on AXSOME THERAPEUTICS INC future price: according to them, AXSM price has a max estimate of 3126.95 MXN and a min estimate of 1481.19 MXN. Read a more detailed AXSOME THERAPEUTICS INC forecast: see what analysts think of AXSOME THERAPEUTICS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AXSOME THERAPEUTICS INC EBITDA is −2.97 B MXN, and current EBITDA margin is −65.07%. See more stats in AXSOME THERAPEUTICS INC financial statements.